The world's largest randomized control trial against COVID-19 using remdesivir, hydroxychloroquine, lopinavir and interferon-β1a appeared to have little or no effect on hospitalized COVID-19 patients. This has again led to search for alternate re-purposed drugs and/or effective “add-on” nutritional supplementation, which can complement or enhance the therapeutic effect of re-purposed drug. Focus has been shifted to therapeutic targets of severe acute respiratory syndrome coronavirus (SARS-CoV-2), which includes specific enzymes and regulators of lipid metabolism. Very recently, fenofibrate (cholesterol-lowering drug), suppressed the SARS-CoV-2 replication and pathogenesis by affecting the pathways of lipid metabolism in lung cells of COVID-19 patients. A preclinical study has shown synergistic effect of quercetin (a flavonoid) and fenofibrate in reducing the cholesterol content, which might be useful in COVID-19 treatment. Based on the scientific literature, use of quercetin and fenofibrate in COVID-19 seems meaningful in pharmaceutical and biomedical research, and warrants basic, experimental and clinical studies. In this article, we have summarized the contemporary findings about drug fenofibrate and its effect on membrane synthesis of COVID-19 virus along with emphasizing on possible synergistic effects of quercetin with fenofibrate.

使用瑞德西韦、羟氯喹、洛匹那韦和干扰素-β1a 进行的世界上最大的针对 COVID-19 的随机对照试验似乎对住院的 COVID-19 患者影响很小或没有影响。这再次导致寻找替代的再利用药物和/或有效的“附加”营养补充剂，它们可以补充或增强再利用药物的治疗效果。重点已转移到严重急性呼吸系统综合症冠状病毒 (SARS-CoV-2) 的治疗靶点，其中包括特定的酶和脂质代谢调节剂。最近，非诺贝特（降胆固醇药）通过影响 COVID-19 患者肺细胞的脂质代谢途径抑制了 SARS-CoV-2 的复制和发病机制。一项临床前研究表明槲皮素（一种黄酮类化合物）和非诺贝特在降低胆固醇含量方面具有协同作用，这可能有助于 COVID-19 治疗。根据科学文献，在 COVID-19 中使用槲皮素和非诺贝特在药物和生物医学研究中似乎很有意义，并且需要进行基础、实验和临床研究。在本文中，我们总结了关于药物非诺贝特及其对 COVID-19 病毒膜合成影响的当代发现，并强调了槲皮素与非诺贝特可能的协同作用。实验和临床研究。在本文中，我们总结了关于药物非诺贝特及其对 COVID-19 病毒膜合成影响的当代发现，并强调了槲皮素与非诺贝特可能的协同作用。实验和临床研究。在本文中，我们总结了关于药物非诺贝特及其对 COVID-19 病毒膜合成影响的当代发现，并强调了槲皮素与非诺贝特可能的协同作用。